Chinese humanoid robot maker surges 600% in trading debut - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号)。如果该手机号尚未注册,将自动创建 FT中文网账号。短信可能需要几分钟送达,验证码15分钟内有效,请耐心等待:
请您阅读我们的用户注册协议和隐私权保护政策,点击下方按钮即视为您接受。
机器人

Chinese humanoid robot maker surges 600% in trading debut

Unitree makes stellar start in Shanghai as investors clamour for shares
00:00

{"text":[[{"start":12.04,"text":"Shares in Chinese humanoid robot maker Unitree surged more than 600 per cent on their trading debut in Shanghai on Wednesday, highlighting a mounting onshore investor frenzy for technology companies."}],[{"start":24.34,"text":"The stock gained as much as 629 per cent before falling back to close 460 per cent higher at Rmb845 ($125)."}],[{"start":41.62,"text":"Unitree’s market capitalisation briefly soared above Rmb400bn ($59bn), putting it among the ranks of China’s most valuable companies."}],[{"start":45.22,"text":"The initial public offering was priced at Rmb150.8 ($22.36) a share, valuing the company at about $9bn ahead of the debut."}],[{"start":55.96,"text":"The tranche of shares for retail investors was more than 5,500 times oversubscribed, which reflected “tremendous investor enthusiasm for the company”, said Kenny Ng, a strategist at Everbright Securities International. “This is partly due to Unitree’s high brand recognition in mainland China.”"}],[{"start":73.88,"text":"Its robots have been shown dancing, jumping and boxing at lunar new year galas, which are among the most-watched events on Chinese television."}],[{"start":81.76,"text":"Valuations for some of China’s newest technology firms are at record highs because of a combination of government support and investor enthusiasm."}],[{"start":90.18,"text":"The surge put Unitree’s trailing price-to-earnings ratio at almost 1,200, underscoring the high expectations for the company’s growth potential."}],[{"start":99,"text":"Unitree shipped 5,500 humanoid robots last year."}],[{"start":102.6,"text":"Rinat Mirzaitov, who recently founded Humanoid Analytics to track android shipments and usage, said Unitree had a “unique niche” as it dominated the market for selling robots to researchers, but it now needed to expand into others."}],[{"start":115.76,"text":"“Where money comes from will be from the household and personal assistant and maybe the industrial and commercial [markets]. Unitree just started the first step,” he said."}],[{"start":124.8,"text":"Investors remain optimistic about the sector’s growth prospects. Kieron Poon, investment director for Asian equities at Aberdeen, said: “We are positive on humanoids.”"}],[{"start":135.64,"text":"He added that component suppliers to robotics firms would have the most benefits: “Right now we’re looking at the upstream for the humanoid supply chain first.”"}],[{"start":144,"text":"Unitree is one of the few listed humanoid robotics companies, with its largest competitor, AgiBot, remaining private. Another rival, UBTech, is listed in Hong Kong."}],[{"start":156,"text":"The IPO made Unitree “a rare pure-play player of humanoid robot[s] in the Chinese A-share stock market”, said Ming Lee, head of Greater China autos and industrials research at BofA Global Research."}],[{"start":169.6,"text":"“This would provide a valuation anchor and a path reference for the subsequent listings of many other Chinese robotics companies.”"}],[{"start":176.6,"text":"The frenzy comes despite the US Federal Communications Commission banning imports of humanoid robots last month in a move widely seen as targeting Chinese products."}],[{"start":186.6,"text":"According to Unitree, overseas revenue accounts for more than 40 per cent of its earnings, with the US making up between 13.3 per cent and 18.4 per cent depending on the year."}],[{"start":203.84,"text":""}]],"url":"https://audio.ftcn.net.cn/album/a_1787125621_8430.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

美债收益率冲击下,欧洲必须自寻出路

埃里安:欧洲不能只盼着大西洋彼岸的借贷成本回落,它必须着手解决自身问题。

AI与通胀:央行行长该担忧到什么程度?

凯恩斯:这取决于一个价值万亿美元问题的答案:AI是否真能带来预期的生产力提升?

印度企业界的乐观情绪站得住脚吗?

印度企业界公开表达的乐观情绪,与家庭和投资者的焦虑情绪之间的落差日益明显。

Lex专栏:中国药企在药品开发领域获得一席之地

外国制药集团如今开始购买中国本土开发创新药物的授权。

特斯拉与太空探索技术公司:以马斯克为中心的庞大企业星系

埃隆•马斯克旗下上市公司的合并有一定道理,但其他股东最终可能不如现在有影响力。

火箭、机器人和风险:马斯克的3.6万亿美元豪赌

全球首富试图促成迄今最大胆的一笔合并交易,但他还需要说服股东和全球监管机构。
设置字号×
最小
较小
默认
较大
最大
分享×